Given the high prevalence of coronary heart disease (CHD) and continuously aging population in Europe, the prevention of morbidity and mortality in patients with established CHD is a major public health objective and the focus of this project.

We aim to significantly reduce the numbers of destructive and expensive events, namely, cardiovascular deaths, myocardial infarctions (MI) and heart failure hospitalizations by using outcome risk and patient characteristics guided prevention in CHD patients.

The specific CoroPrevention objectives are:

  1. Prospectively evaluate clinical utility of personalized prevention in CHD 
  2. Evaluate health economic and social benefits of the personalized prevention in CHD
  3. Discover predictive markers of drug treatment response in CHD
  4. Improve current ESC guidelines based on RCT validated clinical data 
  5. Disseminate the refined prevention program to the attention of practitioners, patients, health care payers and policy makers 


The main methods in CoroPrevention include a personalized prevention program (PPP) designed by the Universities of Hasselt and Oulu, randomized clinical trial (RCT) to pilot the PPP and a novel biomarker based CoroPredict score for identification of very high risk coronary artery disease (CHD) patients.

Included are also health economics and health technology assessments, which are needed for communication and dissemination of results by ESC to physicians, relevant health authorities and policy makers.